Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm: MaPreservFerti (MaPreservFerti)

15 maj 2026 uppdaterad av: Hospices Civils de Lyon

Outcomes for Patients Who Preserved Their Fertility as Part of Cancer Treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon Between 2010 and 2024: an Assessment of Male Parenthood. MaPreservFerti

Improvements in diagnostic methods and cancer treatments have led to a steady increase in survival rates. The 5-year survival rate for men diagnosed with cancer between the ages of 15 and 39 has exceeded 81%. As a result, quality of life-and in particular, addressing the issue of parenthood-has become essential.

Cancer treatments-surgery, radiation therapy, and chemotherapy-can significantly impair fertility. They may cause sexual dysfunction (anejaculation, anerection), androgen deficiency, or permanent impairment of spermatogenesis. Yet the desire for parenthood ranks among the top three life goals of patients newly diagnosed with cancer, and 50% of patients wish to have a child in the future. Preserving male fertility is therefore a crucial issue.

Before puberty, this can be done by taking a testicular tissue sample, although this is still considered experimental. After puberty, a sample taken from ejaculate allows for the storage of sperm straws.

Thus, when a couple wishes to conceive, following a potential reassessment of spermatogenesis if it is impaired, Assisted Reproductive Technology (ART) can be performed with or without the frozen sperm.

According to the literature, the sperm is typically used within 10 years of fertility preservation. Little data has been collected regarding whether men with a history of cancer conceive naturally or not. It is therefore important to gather this information regarding fatherhood, particularly whether men with a history of cancer have used ART or not, and whether frozen sperm was used or not, based on the results of the follow-up semen analysis performed after treatment.

Primary objective To describe fertility-whether spontaneous or following assisted reproductive technology (ART)-with or without the use of preserved gametes, among patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.

Secondary objective:

To assess the population of men who preserved their fertility prior to cancer treatment at the Center for the Study and Preservation of Eggs and Sperm (CECOS) in Lyon between 2010 and 2024, specifically:

  • The number and clinical and epidemiological characteristics of the patients.
  • Describe post-cancer fertility
  • Understand CECOS's care protocols to improve the patient care pathway.
  • Describe the psychological difficulties at the time of collection that prevented the procedure and thus the preservation of fertility.
  • Determine the fate of preserved straws that were not used

Methodology:

  • Retrospective analysis of data from the CECOS in Lyon between 2010 and 2024.
  • Information collected from the database: patient age, indication, type of fertility preservation performed (testicular tissue or ejaculate)
  • Subsequently, a paper and electronic questionnaire was sent to these same patients to collect data on their fertility following fertility preservation.
  • Information collected via the questionnaires: marital status, place of residence, paternity prior to cancer, type of cancer, treatment received, achievement of pregnancy after cancer and method (spontaneous pregnancy, reuse of straws at the center, or ART at another center), donation of gametes to research, or destruction if unused.

The CECOS in Lyon is an integral part of the Department of Reproductive Medicine and Biology at the Hopsices Civils de Lyon.

Population studied: This study focuses on patients with a history of cancer who underwent gonadotoxic treatment and preserved their fertility at the CECOS in Lyon between 2010 and 2024

Inclusion criteria:

This study will include patients who:

  • were between the ages of 18 and 60 at the time of fertility preservation
  • underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
  • underwent fertility preservation in the context of cancer treatment
  • who have indicated their consent to participate in the study by completing the questionnaire

Exclusion criteria:

  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons receiving psychiatric care
  • Persons admitted to a health or social care facility for purposes other than research
  • Adults subject to a legal protection measure (guardianship, conservatorship)

Procedure:

An information sheet will be sent to patients regarding the analysis of their medical data collected during their care, along with a questionnaire (see attached questionnaire) for the collection of prospective data. The materials will be sent either by mail (with a stamped envelope for free return shipping as part of the study) or electronically via a dedicated and secure CECOS email address for email responses.

Number of subjects : 950 Study duration : 1 year

Study location : Center for the Study and Preservation of Eggs and Sperm (CECOS)

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Studietyp

Observationell

Inskrivning (Beräknad)

950

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • France
      • Bron, France, Frankrike, 69500
        • CECOS, Hôpital Femme Mère Enfant
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024.

Beskrivning

Inclusion Criteria:

  • were between the ages of 18 and 60 at the time of fertility preservation
  • Underwent fertility preservation at the CECOS in Lyon between January 1, 2010, and December 31, 2024.
  • underwent fertility preservation in the context of cancer treatment
  • who have indicated their consent to participate in the study by completing the questionnaire

Exclusion Criteria:

  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons receiving psychiatric care
  • Persons admitted to a health or social care facility for purposes other than research
  • Adults subject to a legal protection measure (guardianship, conservatorship)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Targeted patients

Patients who undergone fertility preservation after gonadotoxic cancer treatments in the Lyon CECOS between 2010 and 2024 will receive a self-assessment form.

After completing it they will return it to the center for analysis

The self-assessment form will be sent only once. Patients will return it through a pre-stamped envelope joined to the form

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The fertility of patients who underwent fertility preservation for cancer treatment at the CECOS in Lyon between 2010 and 2024.
Tidsram: Day 1

It will be assessed based on the percentage of patients whose partners had a positive pregnancy test:

  • either spontaneously after 12 months of unprotected intercourse
  • or following Assisted Reproductive Technology (ART):

    • with the use of cryopreserved gametes
    • without the use of cryopreserved gametes, as a follow-up semen analysis allowed for the use of non-frozen gametes
    • with the use of donor sperm.
Day 1

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 juni 2027

Studieregistreringsdatum

Först inskickad

15 maj 2026

Först inskickad som uppfyllde QC-kriterierna

15 maj 2026

Första postat (Faktisk)

22 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 69HCL25_0974
  • 2025-A02363-46 (Annan identifierare: ID-RCB)

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera